Scientists at Michigan Medicine have made a significant breakthrough in treating nonalcoholic fatty liver disease (NAFLD), a ...

Nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH) are the most common causes of chronic liver disease in industrialized countries. NAFLD has ...

Nonalcoholic fatty liver disease (NAFLD ... Nonalcoholic steatohepatitis (NASH) is the progressive form of liver injury that carries a risk for progressive fibrosis, cirrhosis, and end-stage ...

Since symptoms don’t appear until the condition worsens, the only way to detect fatty liver early is through blood tests (LFT ...

In the medical field, terminology not only guides clinical understanding and patient communication but also impacts research, ...

One of these is non-alcoholic steatohepatitis, or NASH, the fatty liver disease that affects millions of people and which is poised to be one of pharma’s next big growth areas. Novartis ramped ...

These organizations can help you educate yourself, spread awareness, and connect with the MASH community to help you better ...

Fatty liver disease, or hepatic steatosis, occurs when excess fat accumulates in liver cells. Commonly associated with ...

Akero Therapeutics (AKRO) reported 96-week data in its trial of advanced MASH patients, and there seem really significant ...

It is the progressive form of non-alcoholic fatty liver disease (NAFLD). NASH can lead to cirrhosis and liver cancer. The gut–liver axis is of crucial importance in health and disease.